根据最新合作协议条款,Summit Therapeutics PLC(以下简称Summit)与其合作伙伴将保持对各自研发产品的完整所有权。该协议采用双向非排他性模式,意味着双方均可独立开展与其他实体的合作,同时保留对自有知识产权的绝对控制权。
这一安排既保障了双方在特定领域的自主运营空间,又为未来潜在的战略协同留下弹性。非排他性条款尤其凸显了合作框架的灵活性,允许各方在遵守协议基础上自由探索多元化的商业机会。
根据最新合作协议条款,Summit Therapeutics PLC(以下简称Summit)与其合作伙伴将保持对各自研发产品的完整所有权。该协议采用双向非排他性模式,意味着双方均可独立开展与其他实体的合作,同时保留对自有知识产权的绝对控制权。
这一安排既保障了双方在特定领域的自主运营空间,又为未来潜在的战略协同留下弹性。非排他性条款尤其凸显了合作框架的灵活性,允许各方在遵守协议基础上自由探索多元化的商业机会。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.